Report cover image

Global Scleroderma Therapeutics Databank Market Report

Publisher Magna Intelligence
Published Apr 26, 2024
Length 100 Pages
SKU # MAIN18750439

Description

Global Scleroderma Therapeutics Databank Market Report


The Scleroderma Therapeutics market was valued at $1,728.6 Million in 2022, and is projected to reach $2,688.8 Million by 2031 growing at a CAGR of 5.07% from 2023 to 2031. Immunosuppressors segment is expected to be the highest contributor to this market, with $1,235.9 Million in 2022, and is anticipated to reach $1,832.6 Million by 2031, registering a CAGR of 4.52%. Prostacyclin Analogues segment is anticipated to reach $77.5 Million by 2031 with the highest CAGR of 8.45%. Immunosuppressors and Endothelin Receptor Antagonists segments collectively expected to account for about 84.0% share of the Scleroderma Therapeutics market in 2022, with the former constituting around 71.5% share. Prostacyclin Analogues and Phosphodiesterase 5 Inhibitors - PHA segments are expected to witness significant growth rates at a CAGR of 8.45% and 6.62% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 6.4% in the overall Scleroderma Therapeutics market in 2022, and is anticipated to reach 7.7% by 2031.

Table of Contents

100 Pages
1. Global Scleroderma Therapeutics Market, By Drug Class
1.1. Overview
1.2. Immunosuppressors
1.2.1 Immunosuppressors Market, By Region
1.2.1.1 North America Immunosuppressors Market, By Country
1.2.1.2 Europe Immunosuppressors Market, By Country
1.2.1.3 Asia-Pacific Immunosuppressors Market, By Country
1.2.1.4 Rest of World Immunosuppressors Market, By Country
1.3. Phosphodiesterase 5 Inhibitors - PHA
1.3.1 Phosphodiesterase 5 Inhibitors - PHA Market, By Region
1.3.1.1 North America Phosphodiesterase 5 Inhibitors - PHA Market, By Country
1.3.1.2 Europe Phosphodiesterase 5 Inhibitors - PHA Market, By Country
1.3.1.3 Asia-Pacific Phosphodiesterase 5 Inhibitors - PHA Market, By Country
1.3.1.4 Rest of World Phosphodiesterase 5 Inhibitors - PHA Market, By Country
1.4. Endothelin Receptor Antagonists
1.4.1 Endothelin Receptor Antagonists Market, By Region
1.4.1.1 North America Endothelin Receptor Antagonists Market, By Country
1.4.1.2 Europe Endothelin Receptor Antagonists Market, By Country
1.4.1.3 Asia-Pacific Endothelin Receptor Antagonists Market, By Country
1.4.1.4 Rest of World Endothelin Receptor Antagonists Market, By Country
1.5. Prostacyclin Analogues
1.5.1 Prostacyclin Analogues Market, By Region
1.5.1.1 North America Prostacyclin Analogues Market, By Country
1.5.1.2 Europe Prostacyclin Analogues Market, By Country
1.5.1.3 Asia-Pacific Prostacyclin Analogues Market, By Country
1.5.1.4 Rest of World Prostacyclin Analogues Market, By Country
1.6. Calcium Channel Blockers
1.6.1 Calcium Channel Blockers Market, By Region
1.6.1.1 North America Calcium Channel Blockers Market, By Country
1.6.1.2 Europe Calcium Channel Blockers Market, By Country
1.6.1.3 Asia-Pacific Calcium Channel Blockers Market, By Country
1.6.1.4 Rest of World Calcium Channel Blockers Market, By Country
1.7. Analgesics
1.7.1 Analgesics Market, By Region
1.7.1.1 North America Analgesics Market, By Country
1.7.1.2 Europe Analgesics Market, By Country
1.7.1.3 Asia-Pacific Analgesics Market, By Country
1.7.1.4 Rest of World Analgesics Market, By Country
1.8. Other Drug Classes
1.8.1 Other Drug Classes Market, By Region
1.8.1.1 North America Other Drug Classes Market, By Country
1.8.1.2 Europe Other Drug Classes Market, By Country
1.8.1.3 Asia-Pacific Other Drug Classes Market, By Country
1.8.1.4 Rest of World Other Drug Classes Market, By Country
2. Global Scleroderma Therapeutics Market, By Indication
2.1. Overview
2.2. Systemic
2.2.1 Systemic Market, By Region
2.2.1.1 North America Systemic Market, By Country
2.2.1.2 Europe Systemic Market, By Country
2.2.1.3 Asia-Pacific Systemic Market, By Country
2.2.1.4 Rest of World Systemic Market, By Country
2.3. Localized
2.3.1 Localized Market, By Region
2.3.1.1 North America Localized Market, By Country
2.3.1.2 Europe Localized Market, By Country
2.3.1.3 Asia-Pacific Localized Market, By Country
2.3.1.4 Rest of World Localized Market, By Country
3. Global Scleroderma Therapeutics Market, By Region
3.1. Overview
3.2. North America
3.2.1 North America Scleroderma Therapeutics Market, By Drug Class
3.2.2 North America Scleroderma Therapeutics Market, By Indication
3.2.3 North America Scleroderma Therapeutics Market, By Country
3.2.3.1 U.S.
3.2.3.1.1 U.S. Scleroderma Therapeutics Market, By Drug Class
3.2.3.1.2 U.S. Scleroderma Therapeutics Market, By Indication
3.2.3.2 Canada
3.2.3.2.1 Canada Scleroderma Therapeutics Market, By Drug Class
3.2.3.2.2 Canada Scleroderma Therapeutics Market, By Indication
3.3. Europe
3.3.1 Europe Scleroderma Therapeutics Market, By Drug Class
3.3.2 Europe Scleroderma Therapeutics Market, By Indication
3.3.3 Europe Scleroderma Therapeutics Market, By Country
3.3.3.1 Germany
3.3.3.1.1 Germany Scleroderma Therapeutics Market, By Drug Class
3.3.3.1.2 Germany Scleroderma Therapeutics Market, By Indication
3.3.3.2 U.K.
3.3.3.2.1 U.K. Scleroderma Therapeutics Market, By Drug Class
3.3.3.2.2 U.K. Scleroderma Therapeutics Market, By Indication
3.3.3.3 France
3.3.3.3.1 France Scleroderma Therapeutics Market, By Drug Class
3.3.3.3.2 France Scleroderma Therapeutics Market, By Indication
3.3.3.4 Italy
3.3.3.4.1 Italy Scleroderma Therapeutics Market, By Drug Class
3.3.3.4.2 Italy Scleroderma Therapeutics Market, By Indication
3.3.3.5 Spain
3.3.3.5.1 Spain Scleroderma Therapeutics Market, By Drug Class
3.3.3.5.2 Spain Scleroderma Therapeutics Market, By Indication
3.3.3.6 Rest of Europe
3.3.3.6.1 Rest of Europe Scleroderma Therapeutics Market, By Drug Class
3.3.3.6.2 Rest of Europe Scleroderma Therapeutics Market, By Indication
3.4. Asia-Pacific
3.4.1 Asia-Pacific Scleroderma Therapeutics Market, By Drug Class
3.4.2 Asia-Pacific Scleroderma Therapeutics Market, By Indication
3.4.3 Asia-Pacific Scleroderma Therapeutics Market, By Country
3.4.3.1 China
3.4.3.1.1 China Scleroderma Therapeutics Market, By Drug Class
3.4.3.1.2 China Scleroderma Therapeutics Market, By Indication
3.4.3.2 Japan
3.4.3.2.1 Japan Scleroderma Therapeutics Market, By Drug Class
3.4.3.2.2 Japan Scleroderma Therapeutics Market, By Indication
3.4.3.3 South Korea
3.4.3.3.1 South Korea Scleroderma Therapeutics Market, By Drug Class
3.4.3.3.2 South Korea Scleroderma Therapeutics Market, By Indication
3.4.3.4 India
3.4.3.4.1 India Scleroderma Therapeutics Market, By Drug Class
3.4.3.4.2 India Scleroderma Therapeutics Market, By Indication
3.4.3.5 Singapore
3.4.3.5.1 Singapore Scleroderma Therapeutics Market, By Drug Class
3.4.3.5.2 Singapore Scleroderma Therapeutics Market, By Indication
3.4.3.6 Rest of Asia
3.4.3.6.1 Rest of Asia Scleroderma Therapeutics Market, By Drug Class
3.4.3.6.2 Rest of Asia Scleroderma Therapeutics Market, By Indication
3.5. Rest of World
3.5.1 Rest of World Scleroderma Therapeutics Market, By Drug Class
3.5.2 Rest of World Scleroderma Therapeutics Market, By Indication
3.5.3 Rest of World Scleroderma Therapeutics Market, By Country
3.5.3.1 Brazil
3.5.3.1.1 Brazil Scleroderma Therapeutics Market, By Drug Class
3.5.3.1.2 Brazil Scleroderma Therapeutics Market, By Indication
3.5.3.2 Mexico
3.5.3.2.1 Mexico Scleroderma Therapeutics Market, By Drug Class
3.5.3.2.2 Mexico Scleroderma Therapeutics Market, By Indication
3.5.3.3 South Africa
3.5.3.3.1 South Africa Scleroderma Therapeutics Market, By Drug Class
3.5.3.3.2 South Africa Scleroderma Therapeutics Market, By Indication
3.5.3.4 Australia
3.5.3.4.1 Australia Scleroderma Therapeutics Market, By Drug Class
3.5.3.4.2 Australia Scleroderma Therapeutics Market, By Indication
3.5.3.5 ROW Countries
3.5.3.5.1 ROW Countries Scleroderma Therapeutics Market, By Drug Class
3.5.3.5.2 ROW Countries Scleroderma Therapeutics Market, By Indication
ROW Countries Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD LIST OF TABLES
TABLE 1. Global Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 2. Immunosuppressors Market Value, By Region, 2022-2031, Million USD
TABLE 3. North America Immunosuppressors Market Value, By Country, 2022-2031, Million USD
TABLE 4. Europe Immunosuppressors Market Value, By Country, 2022-2031, Million USD
TABLE 5. Asia-Pacific Immunosuppressors Market Value, By Country, 2022-2031, Million USD
TABLE 6. Rest of World Immunosuppressors Market Value, By Country, 2022-2031, Million USD
TABLE 7. Phosphodiesterase 5 Inhibitors - PHA Market Value, By Region, 2022-2031, Million USD
TABLE 8. North America Phosphodiesterase 5 Inhibitors - PHA Market Value, By Country, 2022-2031, Million USD
TABLE 9. Europe Phosphodiesterase 5 Inhibitors - PHA Market Value, By Country, 2022-2031, Million USD
TABLE 10. Asia-Pacific Phosphodiesterase 5 Inhibitors - PHA Market Value, By Country, 2022-2031, Million USD
TABLE 11. Rest of World Phosphodiesterase 5 Inhibitors - PHA Market Value, By Country, 2022-2031, Million USD
TABLE 12. Endothelin Receptor Antagonists Market Value, By Region, 2022-2031, Million USD
TABLE 13. North America Endothelin Receptor Antagonists Market Value, By Country, 2022-2031, Million USD
TABLE 14. Europe Endothelin Receptor Antagonists Market Value, By Country, 2022-2031, Million USD
TABLE 15. Asia-Pacific Endothelin Receptor Antagonists Market Value, By Country, 2022-2031, Million USD
TABLE 16. Rest of World Endothelin Receptor Antagonists Market Value, By Country, 2022-2031, Million USD
TABLE 17. Prostacyclin Analogues Market Value, By Region, 2022-2031, Million USD
TABLE 18. North America Prostacyclin Analogues Market Value, By Country, 2022-2031, Million USD
TABLE 19. Europe Prostacyclin Analogues Market Value, By Country, 2022-2031, Million USD
TABLE 20. Asia-Pacific Prostacyclin Analogues Market Value, By Country, 2022-2031, Million USD
TABLE 21. Rest of World Prostacyclin Analogues Market Value, By Country, 2022-2031, Million USD
TABLE 22. Calcium Channel Blockers Market Value, By Region, 2022-2031, Million USD
TABLE 23. North America Calcium Channel Blockers Market Value, By Country, 2022-2031, Million USD
TABLE 24. Europe Calcium Channel Blockers Market Value, By Country, 2022-2031, Million USD
TABLE 25. Asia-Pacific Calcium Channel Blockers Market Value, By Country, 2022-2031, Million USD
TABLE 26. Rest of World Calcium Channel Blockers Market Value, By Country, 2022-2031, Million USD
TABLE 27. Analgesics Market Value, By Region, 2022-2031, Million USD
TABLE 28. North America Analgesics Market Value, By Country, 2022-2031, Million USD
TABLE 29. Europe Analgesics Market Value, By Country, 2022-2031, Million USD
TABLE 30. Asia-Pacific Analgesics Market Value, By Country, 2022-2031, Million USD
TABLE 31. Rest of World Analgesics Market Value, By Country, 2022-2031, Million USD
TABLE 32. Other Drug Classes Market Value, By Region, 2022-2031, Million USD
TABLE 33. North America Other Drug Classes Market Value, By Country, 2022-2031, Million USD
TABLE 34. Europe Other Drug Classes Market Value, By Country, 2022-2031, Million USD
TABLE 35. Asia-Pacific Other Drug Classes Market Value, By Country, 2022-2031, Million USD
TABLE 36. Rest of World Other Drug Classes Market Value, By Country, 2022-2031, Million USD
TABLE 37. Global Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 38. Systemic Market Value, By Region, 2022-2031, Million USD
TABLE 39. North America Systemic Market Value, By Country, 2022-2031, Million USD
TABLE 40. Europe Systemic Market Value, By Country, 2022-2031, Million USD
TABLE 41. Asia-Pacific Systemic Market Value, By Country, 2022-2031, Million USD
TABLE 42. Rest of World Systemic Market Value, By Country, 2022-2031, Million USD
TABLE 43. Localized Market Value, By Region, 2022-2031, Million USD
TABLE 44. North America Localized Market Value, By Country, 2022-2031, Million USD
TABLE 45. Europe Localized Market Value, By Country, 2022-2031, Million USD
TABLE 46. Asia-Pacific Localized Market Value, By Country, 2022-2031, Million USD
TABLE 47. Rest of World Localized Market Value, By Country, 2022-2031, Million USD
TABLE 48. Global Scleroderma Therapeutics Market Value, By Region, 2022-2031, Million USD
TABLE 49. North America Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 50. North America Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 51. North America Scleroderma Therapeutics Market Value, By Country, 2022-2031, Million USD
TABLE 52. U.S. Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 53. U.S. Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 54. Canada Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 55. Canada Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 56. Europe Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 57. Europe Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 58. Europe Scleroderma Therapeutics Market Value, By Country, 2022-2031, Million USD
TABLE 59. Germany Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 60. Germany Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 61. U.K. Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 62. U.K. Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 63. France Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 64. France Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 65. Italy Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 66. Italy Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 67. Spain Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 68. Spain Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 69. Rest of Europe Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 70. Rest of Europe Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 71. Asia-Pacific Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 72. Asia-Pacific Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 73. Asia-Pacific Scleroderma Therapeutics Market Value, By Country, 2022-2031, Million USD
TABLE 74. China Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 75. China Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 76. Japan Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 77. Japan Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 78. South Korea Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 79. South Korea Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 80. India Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 81. India Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 82. Singapore Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 83. Singapore Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 84. Rest of Asia Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 85. Rest of Asia Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 86. Rest of World Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 87. Rest of World Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 88. Rest of World Scleroderma Therapeutics Market Value, By Country, 2022-2031, Million USD
TABLE 89. Brazil Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 90. Brazil Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 91. Mexico Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 92. Mexico Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 93. South Africa Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 94. South Africa Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 95. Australia Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 96. Australia Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
TABLE 97. ROW Countries Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD
TABLE 98. ROW Countries Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD
ROW Countries Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us